MX2023002422A - Farmaco terapeutico para complicaciones motoras en enfermedad de parkinson. - Google Patents

Farmaco terapeutico para complicaciones motoras en enfermedad de parkinson.

Info

Publication number
MX2023002422A
MX2023002422A MX2023002422A MX2023002422A MX2023002422A MX 2023002422 A MX2023002422 A MX 2023002422A MX 2023002422 A MX2023002422 A MX 2023002422A MX 2023002422 A MX2023002422 A MX 2023002422A MX 2023002422 A MX2023002422 A MX 2023002422A
Authority
MX
Mexico
Prior art keywords
parkinson
disease
therapeutic agent
motor complications
motor
Prior art date
Application number
MX2023002422A
Other languages
English (en)
Spanish (es)
Inventor
Mitsumasa Kurita
Yuki Ikeda
Mitsuhiro Nakato
Original Assignee
Sumitomo Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharma Co Ltd filed Critical Sumitomo Pharma Co Ltd
Publication of MX2023002422A publication Critical patent/MX2023002422A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2023002422A 2020-08-31 2021-08-30 Farmaco terapeutico para complicaciones motoras en enfermedad de parkinson. MX2023002422A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020145967 2020-08-31
PCT/JP2021/031722 WO2022045336A1 (ja) 2020-08-31 2021-08-30 パーキンソン病の運動合併症治療薬

Publications (1)

Publication Number Publication Date
MX2023002422A true MX2023002422A (es) 2023-03-22

Family

ID=80353469

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002422A MX2023002422A (es) 2020-08-31 2021-08-30 Farmaco terapeutico para complicaciones motoras en enfermedad de parkinson.

Country Status (10)

Country Link
US (2) US11628169B2 (cg-RX-API-DMAC7.html)
EP (1) EP4218764A4 (cg-RX-API-DMAC7.html)
JP (2) JPWO2022045336A1 (cg-RX-API-DMAC7.html)
KR (1) KR20230058615A (cg-RX-API-DMAC7.html)
CN (1) CN116113402A (cg-RX-API-DMAC7.html)
AU (1) AU2021332775A1 (cg-RX-API-DMAC7.html)
CA (1) CA3189670A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023002422A (cg-RX-API-DMAC7.html)
TW (1) TW202227080A (cg-RX-API-DMAC7.html)
WO (1) WO2022045336A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3168199A1 (en) 2020-02-19 2021-08-26 Eri ICHIBAYASHI Transdermal absorption preparation
JPWO2022045336A1 (cg-RX-API-DMAC7.html) * 2020-08-31 2022-03-03

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507303A (en) 1981-12-22 1985-03-26 Sumitomo Chemical Company, Limited Succinimide derivatives, compositions and method of use
JPS58126865A (ja) 1981-12-22 1983-07-28 Sumitomo Chem Co Ltd 環状イミド誘導体及びその酸付加塩
US5633009A (en) * 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
JPH11228414A (ja) 1998-02-06 1999-08-24 Sumitomo Pharmaceut Co Ltd タンドスピロン経皮剤
JPH11228454A (ja) * 1998-02-17 1999-08-24 Sumitomo Chem Co Ltd アルキニル置換アリールブロミド類の製造方法
JP2002020291A (ja) 2000-06-30 2002-01-23 Sumitomo Pharmaceut Co Ltd 認知機能障害の治療剤
GB0027020D0 (en) * 2000-11-03 2000-12-20 Univ Manchester Treatment of movement disorders
WO2005117886A1 (ja) 2004-06-01 2005-12-15 Hisamitsu Pharmaceutical Co., Inc. 貼付剤
ATE413166T1 (de) 2004-11-22 2008-11-15 Hisamitsu Pharmaceutical Co Transdermales pflaster enthaltend einen schmelzpunktsenkenden hilfsstoff
JP4873871B2 (ja) 2005-02-28 2012-02-08 久光製薬株式会社 粘着剤及び貼付剤
WO2008044336A1 (en) 2006-10-11 2008-04-17 Hisamitsu Pharmaceutical Co., Inc. Crystal-containing adhesive preparation
EP2729176A1 (en) 2011-07-05 2014-05-14 Contera Pharma APS The use of serotonin receptor agonists for treatment of movement disorders
MY169068A (en) 2012-04-18 2019-02-12 Contera Pharma Aps Orally available pharmaceutical formulation suitable for improved management of movement disorders
EP3897641B1 (en) * 2018-12-20 2023-11-15 Contera Pharma A/S Treatment of movement disorders
JP2020145967A (ja) 2019-03-13 2020-09-17 日清食品ホールディングス株式会社 プライマー及び特定昆虫の検出方法
US10758535B1 (en) 2019-04-26 2020-09-01 Sumitomo Dainippon Pharma Co., Ltd. Therapeutic drug for dyskinesia
CA3168199A1 (en) 2020-02-19 2021-08-26 Eri ICHIBAYASHI Transdermal absorption preparation
JPWO2022045336A1 (cg-RX-API-DMAC7.html) * 2020-08-31 2022-03-03

Also Published As

Publication number Publication date
US11628169B2 (en) 2023-04-18
JP2026126306A (ja) 2026-08-04
EP4218764A1 (en) 2023-08-02
WO2022045336A1 (ja) 2022-03-03
US20220062282A1 (en) 2022-03-03
US20230241062A1 (en) 2023-08-03
AU2021332775A9 (en) 2024-09-26
CA3189670A1 (en) 2022-03-03
AU2021332775A1 (en) 2023-04-27
EP4218764A4 (en) 2024-10-02
KR20230058615A (ko) 2023-05-03
JPWO2022045336A1 (cg-RX-API-DMAC7.html) 2022-03-03
CN116113402A (zh) 2023-05-12
TW202227080A (zh) 2022-07-16

Similar Documents

Publication Publication Date Title
MX2025012306A (es) Inhibidores del gen de sarcoma de rata de kirsten (kras) de 2-azabiciclo [2.2.1] heptano
ZA202109010B (en) Compounds and methods for the treatment of covid-19
ZA202403388B (en) Small molecules for treatement of cancer
GEAP202416135A (en) 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors
MY200810A (en) Pyrrolidine compounds
MX2025005792A (es) Combinaciones farmaceuticas y usos de las mismas
PH12023550160A1 (en) Combinations for the Treatment of Cancer
MX2023002323A (es) Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2024003772A (es) Compuestos de imidazopiridazina inhibidores de il-17.
MX2024003770A (es) Compuestos de imidazopiridazina inhibidores de il-17.
ZA202006072B (en) Ret inhibitor for use in treating cancer having a ret alteration
MX2022009197A (es) Metodos de tratamiento para deficiencia de alfa-1 antitripsina.
EA202192928A1 (ru) Терапевтическое лекарственное средство для лечения дискинезии
MX2024014117A (es) Sales de ácido piperidinil-metil-purina-amina-d-tartárico, formas cristalinas y su uso en el tratamiento de enfermedades y condiciones médicas
MX2024005107A (es) Nuevo uso de compuesto de quinazolinona para el tratamiento de cancer.
PH12023550780A1 (en) Line-1 inhibitors to treat disease
MX2024001840A (es) Composiciones para usar en el tratamiento de neoplasias de celulas b.
TW200639159A (en) Treatment of pain
MX2024010615A (es) Sales de un inhibidor de dihidroorotato deshidrogenasa (dhod)
MX2020007817A (es) Prevención y tratamiento del trastorno del sueño.
MX2023009166A (es) Derivados de quinoxalina y sus usos.
GEAP202516820A (en) Prmt5-mta inhibitor
MX2022015146A (es) Tratamiento de la artritis reumatoide.
MX2026000979A (es) Una forma farmaceutica solida de dosificacion bucodispersable de safinamida
WO2022177968A8 (en) Therapeutic methods